South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Day One Biopharmaceuticals is raising $129,999,786.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeremy Bender played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Day One Biopharmaceuticals

Inspired by a call to action from the pediatric oncology community, Day One listens to, and acts in service of the needs of patients, their families, and their treating oncologists. Recognizing that many new treatments can benefit both children and adults with cancer based on a tumor’s underlying biology, Day One prioritizes programs that can be rapidly brought to market for both younger and older patients. We invite pediatric oncology investigators and the parent advocacy community to partner with us to identify the most relevant and valuable new treatments. We will relentlessly follow the data and rigorously evaluate proposed ideas. Our goal is to license and acquire the most promising products from research institutions as well as biotechnology and pharmaceutical companies.

To learn more about Day One Biopharmaceuticals, visit http://dayonebio.com/

Contact:
Jeremy Bender, Chief Executive Officer
650-484-0899
jeremy.bender@dayonebio.com
https://www.linkedin.com/in/jeremy-bender-146206/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved